View Financial HealthOdonate 配当と自社株買い配当金 基準チェック /06Odonate配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • Jan 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Laura Douglass was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Nov 25Independent Director recently sold US$437k worth of stockOn the 19th of November, Aaron Davis sold around 200k shares on-market at roughly US$2.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$386k more than they bought in the last 12 months.分析記事 • Nov 18Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Executive Departure • Aug 06Chief Medical Officer Joseph O’Connell has left the companyOn the 31st of July, Joseph O’Connell's tenure as Chief Medical Officer ended after 3.9 years in the role. As of March 2021, Joseph still personally held only 3.61k shares (US$12k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.38 years.分析記事 • Jun 09Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 09We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Jan 27New 90-day high: US$21.88The company is up 47% from its price of US$14.90 on 28 October 2020. The American market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period.分析記事 • Jan 07Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of SharesWhilst it may not be a huge deal, we thought it was good to see that the Odonate Therapeutics, Inc. ( NASDAQ:ODT...Recent Insider Transactions • Jan 07Independent Director recently bought US$51k worth of stockOn the 29th of December, Craig Johnson bought around 3k shares on-market at roughly US$17.00 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Recent Insider Transactions • Jan 02Independent Director recently bought US$51k worth of stockOn the 29th of December, Craig Johnson bought around 3k shares on-market at roughly US$17.00 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Is New 90 Day High Low • Dec 30New 90-day high: US$17.28The company is up 29% from its price of US$13.43 on 30 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 11New 90-day high: US$16.81The company is up 13% from its price of US$14.92 on 11 September 2020. The American market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.分析記事 • Dec 09Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Sep 18New 90-day low: US$14.77The company is down 64% from its price of US$41.51 on 19 June 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.決済の安定と成長配当データの取得安定した配当: ODTCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ODTCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Odonate 配当利回り対市場ODTC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ODTC)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (ODTC) (最長3年)n/a注目すべき配当: ODTCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ODTCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ODTCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ODTCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/04 04:25終値2025/02/04 00:00収益2021/09/30年間収益2020/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Odonate, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Dana FlandersGoldman SachsMichael YeeJefferies LLCEric SchmidtTD Cowen
Board Change • Jan 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Laura Douglass was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Nov 25Independent Director recently sold US$437k worth of stockOn the 19th of November, Aaron Davis sold around 200k shares on-market at roughly US$2.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$386k more than they bought in the last 12 months.
分析記事 • Nov 18Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Executive Departure • Aug 06Chief Medical Officer Joseph O’Connell has left the companyOn the 31st of July, Joseph O’Connell's tenure as Chief Medical Officer ended after 3.9 years in the role. As of March 2021, Joseph still personally held only 3.61k shares (US$12k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.38 years.
分析記事 • Jun 09Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Mar 09We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Jan 27New 90-day high: US$21.88The company is up 47% from its price of US$14.90 on 28 October 2020. The American market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period.
分析記事 • Jan 07Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of SharesWhilst it may not be a huge deal, we thought it was good to see that the Odonate Therapeutics, Inc. ( NASDAQ:ODT...
Recent Insider Transactions • Jan 07Independent Director recently bought US$51k worth of stockOn the 29th of December, Craig Johnson bought around 3k shares on-market at roughly US$17.00 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Recent Insider Transactions • Jan 02Independent Director recently bought US$51k worth of stockOn the 29th of December, Craig Johnson bought around 3k shares on-market at roughly US$17.00 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Is New 90 Day High Low • Dec 30New 90-day high: US$17.28The company is up 29% from its price of US$13.43 on 30 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 11New 90-day high: US$16.81The company is up 13% from its price of US$14.92 on 11 September 2020. The American market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
分析記事 • Dec 09Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Sep 18New 90-day low: US$14.77The company is down 64% from its price of US$41.51 on 19 June 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.